Roivant Expands Brepocitinib Trials into LPP as Batoclimab Fails in TED

Event summary

  • Roivant initiates Phase 2b/3 trial for brepocitinib in lichen planopilaris (LPP), a rare inflammatory scalp disorder with no FDA-approved treatments.
  • Brepocitinib becomes the fourth indication in late-stage development for the drug, following dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis.
  • Immunovant's Phase 3 studies for batoclimab in thyroid eye disease (TED) fail to meet primary endpoint, though safety results align with prior findings.
  • Roivant expects FDA Priority Review decision for brepocitinib in dermatomyositis by Q3 2026.

The big picture

Roivant's expansion of brepocitinib into LPP underscores its strategy of targeting high-unmet-need orphan diseases with a single therapeutic. The setback in TED highlights the challenges of developing treatments for complex autoimmune conditions, while the upcoming FDA decision for dermatomyositis could set the tone for brepocitinib's broader commercial potential. The company's ability to balance multiple late-stage trials will be critical to its long-term success.

What we're watching

Pipeline Diversification
Whether Roivant can successfully expand brepocitinib's reach into multiple high-morbidity orphan conditions.
Regulatory Momentum
The pace at which brepocitinib advances through FDA reviews across its multiple indications.
Therapeutic Strategy
How Immunovant pivots batoclimab's development following the TED trial setback.